Rudmik L, Smith TL. Quality of life in patients with chronic rhinosinusitis. Curr Allergy Asthma Rep. 2011;11(3):247–52.

Article  PubMed  Google Scholar 

Grayson JW, Cavada M, Harvey RJ. Clinically relevant phenotypes in chronic rhinosinusitis. J Otolaryngol Head Neck Surg. 2019;48(1):1–10. https://doi.org/10.1186/s40463-019-0350-y.

Article  Google Scholar 

Chen S, Zhou A, Emmanuel B, Thomas K, Guiang H. Systematic literature review of the epidemiology and clinical burden of chronic rhinosinusitis with nasal polyposis. Curr Med Res Opin. 2020. https://doi.org/10.1080/03007995.2020.1815682.

Article  PubMed  PubMed Central  Google Scholar 

Stevens WW, Schleimer RP, Kern RC. Chronic rhinosinusitis with nasal polyps. J allergy Clin Immunol Pract. 2016;4(4):565.

Article  PubMed  PubMed Central  Google Scholar 

Stevens WW, Peters AT, Hirsch AG, Nordberg CM, Schwartz BS, Mercer DG, et al. Clinical characteristics of patients with chronic rhinosinusitis with nasal polyps, asthma, and aspirin-exacerbated respiratory disease. J allergy Clin Immunol Pract. 2017;5(4):1061-1070.e3.

Article  PubMed  PubMed Central  Google Scholar 

DeConde AS, Mace JC, Levy JM, Rudmik L, Alt JA, Smith TL. Prevalence of polyp recurrence after endoscopic sinus surgery for chronic rhinosinusitis with nasal polyposis. Laryngoscope. 2017;127(3):550–5.

Article  PubMed  Google Scholar 

Ren L, Zhang N, Zhang L, Bachert C. Biologics for the treatment of chronic rhinosinusitis with nasal polyps—state of the art. World Allergy Organ J 2019;12(8).

Patel GB, Peters AT. The role of biologics in chronic rhinosinusitis with nasal polyps. Ear Nose Throat J. 2021;100(1):44–7.

Article  PubMed  Google Scholar 

Fokkens WJ, Lund V, Bachert C, Mullol J, Bjermer L, Bousquet J, et al. EUFOREA consensus on biologics for CRSwNP with or without asthma. Allergy. 2019;74(12):2312–9.

Article  PubMed  Google Scholar 

Oykhman P, Paramo FA, Bousquet J, Kennedy DW, Brignardello-Petersen R, Chu DK. Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: a systematic review and network meta-analysis. J Allergy Clin Immunol. 2022;149(4):1286–95.

Article  CAS  PubMed  Google Scholar 

Bachert C, Han JK, Desrosiers M, Hellings PW, Amin N, Lee SE, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet (London, England). 2019;394(10209):1638–50.

Article  CAS  PubMed  Google Scholar 

Giovannini M, Mori F, Barni S, De Martino M, Novembre E. Omalizumab and mepolizumab in the landscape of biological therapy for severe asthma in children: how to choose? Ital J Pediatr. 2019;45(1):1–9. https://doi.org/10.1186/s13052-019-0737-4.

Article  Google Scholar 

Yong M, Wu YQ, Howlett J, Ballreich J, Walgama E, Thamboo A. Cost-effectiveness analysis comparing dupilumab and aspirin desensitization therapy for chronic rhinosinusitis with nasal polyposis in aspirin-exacerbated respiratory disease. Int Forum Allergy Rhinol. 2021;11(12):1626–36.

Article  PubMed  Google Scholar 

Scangas GA, Wu AW, Ting JY, Metson R, Walgama E, Shrime MG, et al. Cost utility analysis of dupilumab versus endoscopic sinus surgery for chronic rhinosinusitis with nasal polyps. Laryngoscope. 2021;131(1):E26-33.

Article  CAS  PubMed  Google Scholar 

Thamboo A, Kilty S, Witterick I, Chan Y, Chin CJ, Janjua A, et al. Canadian Rhinology Working Group consensus statement: biologic therapies for chronic rhinosinusitis. J Otolaryngol Head Neck Surg. 2021;50(1):1–9. https://doi.org/10.1186/s40463-021-00493-2.

Article  Google Scholar 

Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated health economic evaluation reporting standards (CHEERS) statement. BMJ. 2013. https://doi.org/10.1136/bmj.f1049.

Article  PubMed  Google Scholar 

Verma V, Sprave T, Haque W, Simone CB, Chang JY, Welsh JW, et al. A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors. J Immunother Cancer. 2018;6(1):128.

Article  PubMed  PubMed Central  Google Scholar 

Attema AE, Brouwer WBF, Claxton K. Discounting in Economic Evaluations. Pharmacoeconomics. 2018;36(7):745.

Article  PubMed  PubMed Central  Google Scholar 

Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. J Am Med Assoc. 1996;276(16):1339–41.

Article  CAS  Google Scholar 

Dalziel K, Stein K, Round A, Garside R, Royle P. Endoscopic sinus surgery for the excision of nasal polyps: a systematic review of safety and effectiveness. Am J Rhinol. 2006;20:506–19.

Article  PubMed  Google Scholar 

Rudmik L, Soler ZM, Mace JC, Schlosser RJ, Smith TL. Economic evaluation of endoscopic sinus surgery versus continued medical therapy for refractory chronic rhinosinusitis. Laryngoscope. 2015;125(1):25–32.

Article  PubMed  Google Scholar 

Stankiewicz JA, Lal D, Connor M, Welch K. Complications in endoscopic sinus surgery for chronic rhinosinusitis: a 25-year experience. Laryngoscope. 2011;121:2684–701.

Article  PubMed  Google Scholar 

Lindstrom DR, Toohill RJ, Loehrl TA, Smith TL. Management of cerebrospinal fluid rhinorrhea: the Medical College of Wisconsin experience. Laryngoscope. 2004;114:969–74.

Article  PubMed  Google Scholar 

Ramakrishnan VR, Kingdom TT, Nayak JV, Hwang PH, Orlandi RR. Nationwide incidence of major complications in endoscopic sinus surgery. Int Forum Allergy Rhinol. 2012;2(1):34–9.

Article  PubMed  Google Scholar 

Gevaert P, Omachi TA, Corren J, Mullol J, Han J, Lee SE, et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol. 2020;146(3):595–605.

Article  CAS  PubMed  Google Scholar 

Han JK, Bachert C, Fokkens W, Desrosiers M, Wagenmann M, Lee SE, et al. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021;9(10):1141–53.

Article  CAS  PubMed  Google Scholar 

Murphy LB, Cisternas MG, Pasta DJ, Helmick CG, Yelin EH. Medical expenditures and earnings losses among US adults with arthritis in 2013. Arthritis Care Res [Internet]. 2018;70(6):869–76. https://pubmed-ncbi-nlm-nih-gov.proxy1.library.jhu.edu/28950426/.

Patel DA, Holdford DA, Edwards E, Carroll N V. Estimating the economic burden of food-induced allergic reactions and anaphylaxis in the United States. J Allergy Clin Immunol [Internet]. 2011;128(1):110–115.e5. https://pubmed-ncbi-nlm-nih-gov.proxy1.library.jhu.edu/21489610/.

Bell CF, Lau M. Clinical and economic characteristics of patients diagnosed with eosinophilic granulomatosis with polyangiitis (EGPA, formerly churg-strauss syndrome) in the United States. Arthritis Rheumatol [Internet]. 2018;70:1949–50. http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emexa&NEWS=N&AN=626434784.

Smith AF, Waycaster C. Estimate of the direct and indirect annual cost of bacterial conjunctivitis in the United States. BMC Ophthalmol [Internet]. 2009;9(1). https://pubmed-ncbi-nlm-nihgov.proxy1.library.jhu.edu/19939250/.

Crump RT, Lai E, Liu G, Janjua A, Sutherland JM. Establishing utility values for the 22-item Sino-Nasal Outcome Test (SNOT-22) using a crosswalk to the EuroQol–five-dimensional questionnaire–three-level version (EQ-5D-3L). Int Forum Allergy Rhinol. 2017;7(5):480–7.

Article  PubMed  Google Scholar 

Drug Benefit Prices (DBPs) for products reimbursed under the EAP [Internet]. Ontario Ministry of Health. https://health.gov.on.ca/en/pro/programs/drugs/odbf/odbf_except_access.aspx. Accessed 30 May 2022.

Nucala (mepolizumab). Product Monograph [Internet]. GlaxoSmithKline. 2021. https://health-products.canada.ca/dpd-bdpp/index-eng.jsp. Accessed 30 May 2022.

Dupixent (dupilumab). Product Monograph [Internet]. Snofi-Aventis Canada Inc. 2022. https://health-products.canada.ca/dpd-bdpp/index-eng.jsp. Accessed 30 May 2022.

Xolair (omalizumab). Product Monograph [Internet]. Novartis Pharma Canada. 2021 https://health-products.canada.ca/dpd-bdpp/index-eng.jsp. Accessed 30 May 2022.

Au J, Rudmik L. Cost of outpatient endoscopic sinus surgery from the perspective of the Canadian government: a time-driven activity-based costing approach. Int Forum Allergy Rhinol. 2013;3(9):748–54.

Article  PubMed  Google Scholar 

Bachert C, Han JK, Desrosiers M, Hellings PW, Amin N, Lee SE, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet (London, England). 2019;394(10209):1638–50.

Article  CAS  PubMed  Google Scholar 

Efficacy and Safety of Depemokimab (GSK3511294) in participants with chronic rhinosinusitis with nasal polyps - full text view—clinicaltrials.gov [Internet]. https://www.clinicaltrials.gov/ct2/show/NCT05274750. Accessed 10 Aug 2022.

McQueen RB, Sheehan DN, Whittington MD, van Boven JFM, Campbell JD. Cost-effectiveness of biological asthma treatments: a systematic review and recommendations for future economic evaluations. Pharmacoeconomics. 2018;36:957–71. https://doi.org/10.1007/s40273-018-0658-x.

Article  PubMed  Google Scholar 

Alobid I, Cardelus S, Benítez P, Guilemany JM, Roca-Ferrer J, Picado C, et al. Persistent asthma has an accumulative impact on the loss of smell in patients with nasal polyposis. Rhinology. 2011;49(5):519–24.

Article  PubMed  Google Scholar 

Bhattacharyya N, Villeneuve S, Joish VN, Amand C, Mannent L, Amin N, et al. Cost burden and resource utilization in patients with chronic rhinosinusitis and nasal polyps. Laryngoscope. 2019;129(9):1969–75.

Article  PubMed  PubMed Central  Google Scholar 

Scangas GA, Remenschneider AK, Su BM, Shrime MG, Metson R. The impact of asthma on the cost effectiveness of surgery for chronic rhinosinusitis with nasal polyps. Int Forum Allergy Rhinol. 2017;7(11):1035–44.

Article  PubMed  Google Scholar 

Wang M, Bu X, Luan G, Lin L, Wang Y, Jin J, et al. Distinct type 2-high inflammation associated molecular signatures of chronic rhinosinusitis with nasal polyps with comorbid asthma. Clin Transl Allergy. 2020;10(1):26.

Article  PubMed  PubMed Central  Google Scholar 

Claudia C, Campisi R, Nolasco S, Heffler E, Valenti G, Pelaia C, et al. Omalizumab versus mepolizumab in severe asthma: a propensity score matched efficiency retrospective cohort study. Eur Respir J. 2020;56(suppl 64):2218.

Google Scholar 

Chapman KR, Albers FC, Chipps B, Muñoz X, Devouassoux G, Bergna M, et al. The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma. Allergy. 2019;74(9):1716–26.